Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center
| Autor: | Jasmien Cornillie, Agnieszka Wozniak, Patrick Schöffski, Tom van Cann, Daphne Hompes, Raf Sciot, Ignace Vergote, Maria Debiec-Rychter |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Leiomyosarcoma Male Cancer Research medicine.medical_specialty Anthracycline Systemic therapy Metastasis Tertiary Care Centers Young Adult 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Outcome Assessment Health Care medicine Humans 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over business.industry Soft tissue sarcoma Palliative Care Hematology Middle Aged Prognosis medicine.disease Progression-Free Survival body regions medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Abdomen Female Radiology Metastasectomy business Progressive disease |
| Zdroj: | Oncology Research and Treatment. 41:206-213 |
| ISSN: | 2296-5262 2296-5270 |
| Popis: | Background: Leiomyosarcoma is a common subtype of soft tissue sarcoma originating from smooth muscle. We evaluated the clinical course and treatment outcome of patients with metastatic leiomyosarcoma. Methods: We retrospectively reviewed the records of patients at the University Hospitals Leuven. Results: We identified 122 patients with metastatic leiomyosarcoma, 77 female, median age 59.5 years. Most patients developed leiomyosarcoma in the extremities (35%), the uterus (20%) or the abdomen (19%); 69% developed metachronous metastasis, 31% had synchronous metastatic disease. Most patients (74%) received palliative systemic therapy. The most common first-line treatments were doxorubicin (n = 47) and an anthracycline combined with an alkylator (n = 28). The objective response rate to first-line palliative systemic therapy was 20% and the median progression-free survival was 4.9 months (range 0.1-17.1). The median survival from diagnosis of metastasis was 20.5 months (range 0.4-126.9). On multivariate analysis, metachronous disease, no progressive disease as best response to first-line treatment, the possibility of metastasectomy with curative intent and use of palliative radiotherapy were indicators for better survival. Conclusion: The prognosis of patients with metastatic leiomyosarcoma is limited and objective responses to first-line systemic therapy are rare. The treatment of metastatic leiomyosarcoma remains an unmet medical need. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |